The Journal of Clinical and Experimental Pathology (ISSN: 2161-0681) deals with research on infectious disorders associated with immune system and immunological disorders, infectious diseases, treatment of infectious diseases, infectious medicine, epidemiology, diagnostic tests of infectious diseases, infection control, pathophysiology, clinical pathology , preventive medicine. Clinical Pathology deals with patient care, diagnostic services, novel treatments and research on immune infections. Journal of Clinical & Experimental Pathology covers all areas of clinical and experimental pathology. Articles such as research papers, review articles, commentaries and short communications leading to the development of Journal of clinical and experimental pathology.

Molecular pathology is a branch of pathology which is focused in the study and diagnosis of disease through the examination of molecules within organs, tissues or bodily fluids. Molecular pathology shares some aspects of practice with both anatomic pathology and clinical pathology, molecular biology, biochemistry, proteomics and genetics, and is sometimes considered a "crossover" discipline. It is multi-disciplinary in nature and focuses mainly on the sub-microscopic aspects of disease. Molecular pathology is commonly used in diagnosis of cancer and infectious diseases. Techniques are numerous but include quantitative polymerase chain reaction (qPCR), multiplex PCR, DNA microarray, in situ hybridization, in situ RNA sequencing, DNA sequencing, antibody based immunofluorescence tissue assays, molecular profiling of pathogens, and analysis of bacterial genes for antimicrobial resistance.

Through molecular and genetic approaches, molecular pathology techniques are used across a variety of specialties to diagnose and assess risk for a multitude of diseases. Some of the applications in this arena include risk assessment for familial cancer, prenatal and preimplantation diagnosis, and the identification of certain neurologic disorders. This type of testing can also be utilized to assess malignancies for staging or diagnostic uses. Personalized medicine, utilizing strategies that include molecular pathology techniques, can use specific information related to the patient’s tumor to help diagnose, plan treatment, assess the effectiveness of a treatment, or develop a prognosis, according to the National Cancer Institute. Targeted therapies can even be used to treat specific classes of cancer cells, or identify tumor markers that can help diagnose cancer.

The Molecular Pathology Laboratory offers molecular diagnostic testing for a variety of clinical indications across the health-care continuum, including testing for disease susceptibility, population screening, diagnosis, prognosis, therapeutic decision making, and disease monitoring. The test menu has many applications in the areas of hereditary diseases, neoplastic diseases, infectious diseases, and for identity testing. The laboratory uses a spectrum of molecular techniques and platforms to evaluate nucleic acids isolated from patient samples, including real-time PCR, capillary electrophoresis, and pyrosequencing.

The Molecular Pathology Laboratory works closely with other laboratories in the Division of Precision and Computational Diagnostics, including the Center for Personalized Diagnostics and the Cytogenetics Laboratory, to provide integrated and cutting-edge precision molecular and genomic diagnostic services to patients. The testing of molecular pathology includes Molecular Genetic Testing, Identity Testing and Molecular Virology Testing. Integration of "molecular pathology" and "epidemiology" led to an interdisciplinary field, called as "molecular pathological epidemiology" (MPE), which represents integrative molecular biologic and population health science.

Pathology and epidemiology share the same goal of elucidating etiology of disease, and MPE aims to achieve this goal at molecular, individual and population levels. Typically, MPE utilizes tissue pathology resources and data within existing epidemiology studies. Molecular epidemiology broadly encompasses MPE and conventional-type molecular epidemiology with the use of traditional disease designation systems. Disease evolution is an inherently heterogeneous process. Each patient has a unique disease process, considering the uniqueness of the exposome and its unique influence on molecular pathologic process. This concept has been adopted in clinical medicine along with precision medicine and personalized medicine.

On the occasion of its 10 years, Successful Journey, Journal of Clinical and Experimental Pathology decided to provide a partial waiver on its article processing charges to promote quality research from across the nations of the globe to encourage the latest research in the field of Infections, Diseases and Medicine. Journal of Clinical and Experimental Pathology also planning to release a special issue on its new approaches.

Regards,

Robert Solomon

Editorial office

Journal of Clinical and Experimental Pathology

E-mail: pathol@eclinicalsci.com

Reach Us: +1-947-333-4405